Related Experiment Video

Updated: Jun 22, 2026

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours

Sebastian Bauer1, Thomas Mühlenberg, Michael Leahy

  • 1Sarcoma Centre, West German Cancer Centre, University Hospital Essen, Essen, Germany. sebastian.bauer@uni-due.de

European Urology
|June 30, 2009
PubMed
Abstract

Insights

Murine double minute 2 (Mdm2) inhibitors like nutlin-3 show promise for treating nonseminomatous testicular germ cell tumours (TGCTs) with wild-type p53. Combining Mdm2 inhibition with cisplatin enhances apoptosis in these TGCT models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Advanced testicular germ cell tumours (TGCTs), particularly nonseminomas, often show poor response to cisplatin chemotherapy.
  • Novel agents have yielded limited improvements, and most TGCTs have low p53 levels without mutations.
  • Murine double minute 2 (Mdm2) inhibitors can induce apoptosis in tumors with wild-type p53.

Purpose of the Study:

  • To evaluate the therapeutic potential of Mdm2 inhibition in nonseminoma-derived TGCT cell lines.
  • To assess the efficacy of the Mdm2 inhibitor nutlin-3, alone and combined with cisplatin.
  • To investigate the impact on p53 pathway activation, proliferation, and apoptosis.

Main Methods:

  • Nutlin-3 was tested on TGCT cell lines with wild-type (NT2, 2102EP) and mutant (NCCIT) p53.
  • Cellular responses including p53 pathway activation, proliferation, and apoptosis were analyzed.
  • Combination therapy with nutlin-3 and cisplatin was evaluated.

Main Results:

  • Nutlin-3 demonstrated significant activity against wild-type p53 cell lines (IC50 2.8 μM) but not mutant p53 lines.
  • Combination therapy showed additive effects in wild-type p53 cells, correlating with p53 and p21 induction.
  • Nutlin-3 and cisplatin additively induced apoptosis in wild-type p53 TGCT cells.

Conclusions:

  • Pharmacologic Mdm2 inhibition is a promising strategy for high-risk nonseminomatous TGCT with wild-type p53.
  • Nutlin-3 shows specific efficacy in TGCT models with functional p53.
  • Further development of Mdm2 inhibitors is warranted for this patient population.

More Related Videos

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma09:06

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...